Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA
12 juil. 2021 16h01 HE
|
Equillium
Single pivotal Phase 3 study in acute graft-versus-host disease tosupport filing of biologics license application On track to initiate study in Q4 2021 LA JOLLA, Calif., July 12, 2021 (GLOBE...
Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease
11 juin 2021 07h00 HE
|
Equillium
Itolizumab continues to demonstrate favorable safety and efficacy profile Rapid and durable responses resulted in clinically meaningful reduction in corticosteroid use Data support clinical...
Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry
10 juin 2021 08h00 HE
|
Equillium
LA JOLLA, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium to Present at the JMP Securities Life Sciences Conference
09 juin 2021 08h00 HE
|
Equillium
LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases
07 juin 2021 08h00 HE
|
Equillium
LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11
03 juin 2021 08h00 HE
|
Equillium
Presentation and conference call will include topline data from all cohorts The risk-benefit profile observed supports advancing development of itolizumab in first-line therapy LA JOLLA,...
Equillium to Present at the Jefferies Virtual Healthcare Conference
26 mai 2021 08h00 HE
|
Equillium
LA JOLLA, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Presents Multiple Posters at the 104th Annual Meeting of the American Association of Immunologists
17 mai 2021 08h00 HE
|
Equillium
Research highlights itolizumab’s novel mechanism of action and its effect on modulating T cell responses through inhibition of the CD6-ALCAM pathway The development of a pharmacodynamic biomarker...
Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update
13 mai 2021 16h02 HE
|
Equillium
Announced favorable data from Phase 1b EQUALISE study in patients with systemic lupus erythematosus Cash runway into the second half of 2023 Multiple data and regulatory catalysts through the...
Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association
13 mai 2021 08h00 HE
|
Equillium
LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...